Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An intranasal ASO therapeutic targeting SARS-CoV-2
Chi Zhu, Justin Y. Lee, Jia Z. Woo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development
Anaïs M. Quéméner, Maria Laura Centomo, Scott L. Sax, et al.
Molecules (2022) Vol. 27, Iss. 2, pp. 536-536
Open Access | Times Cited: 64
The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression
Lucija Bujanic, Olga Shevchuk, Nicolai von Kügelgen, et al.
RNA (2022) Vol. 28, Iss. 5, pp. 766-779
Open Access | Times Cited: 50
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Vignesh Hariharan, Minwook Shin, Ching‐Wen Chang, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 11
Open Access | Times Cited: 32
Antiviral Therapy of COVID-19
Georgii Gudima, И.А. Кофиади, I.P. Shilovskiy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8867-8867
Open Access | Times Cited: 24
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 24
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies
Mamta Panda, Elora Kalita, Satyendra Singh, et al.
Life Sciences (2022) Vol. 305, pp. 120761-120761
Open Access | Times Cited: 36
Structural and Functional RNA Motifs of SARS-CoV-2 and Influenza A Virus as a Target of Viral Inhibitors
Izabela Szczesniak, Agnieszka Baliga-Gil, Aleksandra Jarmolowicz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1232-1232
Open Access | Times Cited: 16
Discovery and Quantification of Long-Range RNA Base Pairs in Coronavirus Genomes with SEARCH-MaP and SEISMIC-RNA
Matthew F. Allan, Justin Aruda, Jesse Plung, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis
Pierre‐Marie Boutanquoi, Lenny Pommerolle, Lucile Dondaine, et al.
British Journal of Pharmacology (2025)
Open Access
Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome
Kentaro Tojo, Natsuhiro Yamamoto, Nao Tamada, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105748-105748
Open Access | Times Cited: 22
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
Yuanyuan Qiao, Jesse W. Wotring, Charles J. Zhang, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281281-e0281281
Open Access | Times Cited: 14
High-resolution structure of stem-loop 4 from the 5′-UTR of SARS-CoV-2 solved by solution state NMR
Jennifer Vögele, Daniel Hymon, Jason Martins, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 20, pp. 11318-11331
Open Access | Times Cited: 14
RNA levers and switches controlling viral gene expression
Matthew F. Allan, Amir Brivanlou, Silvi Rouskin
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 4, pp. 391-406
Open Access | Times Cited: 12
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities
Jiaojiao Dai, Xiangyi Jiang, Edeildo Ferreira da Silva‐Júnior, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104074-104074
Closed Access | Times Cited: 4
Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences
Shalakha Hegde, Zhichao Tang, Junxing Zhao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 30
Translational Control of COVID-19 and Its Therapeutic Implication
Dejiu Zhang, Lei Zhu, Yin Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics
Benjamin Ayodipupo Babalola, Oluwamayowa S. Akinsuyi, Elizabeth Oreoluwa Folajimi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115099-115099
Open Access | Times Cited: 10
Effects of Sulforaphane on SARS‑CoV‑2 infection and NF‑κB dependent expression of genes involved in the COVID‑19 ‘cytokine storm’
Jessica Gasparello, Giovanni Marzaro, Chiara Papi, et al.
International Journal of Molecular Medicine (2023) Vol. 52, Iss. 3
Open Access | Times Cited: 10
Harnessing non-Watson–Crick’s base pairing to enhance CRISPR effectors cleavage activities and enable gene editing in mammalian cells
Shuliang Gao, Huiwen Guan, Hanan Bloomer, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 121, Iss. 2
Open Access | Times Cited: 8
Isoform-specific RNA structure determination using Nano-DMS-MaP
Anne-Sophie Gribling-Burrer, Patrick Bohn, Redmond P. Smyth
Nature Protocols (2024) Vol. 19, Iss. 6, pp. 1835-1865
Closed Access | Times Cited: 2
Discovery and Quantification of Long-Range RNA Base Pairs in Coronavirus Genomes with SEARCH-MaP and SEISMIC-RNA
Silvi Rouskin, Matthew F. Allan, Justin Aruda, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Biopolymer-based coating materials for antiviral and antifungal applications: Recent advances in formulations and characterization
Zarin Tasnim Juthi, Mahe Jabeen, Md. Reazul Islam, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 155000-155000
Closed Access | Times Cited: 2
Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Sophie Dhorne‐Pollet, Christopher J. Fitzpatrick, Bruno R. da Costa, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 13
Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses
Soree Park, Seong Ho Kim, Mehrangiz Dezhbord, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 7
Natural Killer Cell‐Derived Extracellular Vesicles as Potential Anti‐Viral Nanomaterials
Siyoung A. Lim, Nathan Ho, Sophia Chen, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 19
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top